Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

Summary

The primary objective of the study is to examine the efficacy of ruxolitinib in patients with sclerotic chronic graft-versus-host disease (GVHD).

Timeline

Start

2018-09-05

Primary completion

2022-01-22

Completion

2023-06-12

Publications

• Bhatt VR, Shostrom VK, Choe HK, Hamilton BK, Gundabolu K, Maness LJ, Kumar V, Mahato RI, Smith LM, Nishihori T, Lee SJ. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. J Clin Oncol. 2024 Nov 20;42(33):3977-3985. doi: 10.1200/JCO.24.00205. Epub 2024 Aug 16.

Drugs

Indications